FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2025/12/099387 [Registered on: 18/12/2025] Trial Registered Prospectively
Last Modified On: 07/01/2026
Post Graduate Thesis  Yes 
Type of Trial  Observational 
Type of Study   Cohort Study 
Study Design  Single Arm Study 
Public Title of Study   Choosing the Right Antibiotic Based on Lab Tests to Improve Patient Care 
Scientific Title of Study   Antibiotic Susceptibility Testing guided Antibiotics Utilization Evaluation 
Trial Acronym  NIL 
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Anmoljot Singh 
Designation  Pharm D Intern 
Affiliation  Indus International Hospital 
Address  Department of clinical trial. Indus International hospital Chandigarh Ambala Highway Derabassi SAS Nagar Rupnagar PUNJAB 140507 India
Department of clinical trial. Indus International hospital Chandigarh Ambala Highway Derabassi SAS Nagar Rupnagar PUNJAB 140507 India
Rupnagar
PUNJAB
140507
India 
Phone  7888687475  
Fax    
Email  anmolgill3101@gmail.com  
 
Details of Contact Person
Scientific Query  
Name  Dr Parminder Kaur 
Designation  Medical Superintendent 
Affiliation  Indus International Hospital 
Address  Admin Department Chandigarh Indus International hospital Ambala Highway Derabassi SAS Nagar Rupnagar PUNJAB 140507 India
Admin Department Chandigarh Indus International hospital Ambala Highway Derabassi SAS Nagar Rupnagar PUNJAB 140507 India
Rupnagar
PUNJAB
140507
India 
Phone  8872735888  
Fax    
Email  msiih@indushospitals.com   
 
Details of Contact Person
Public Query  
Name  Avantika Chandra 
Designation  Manager Clinical Research Department 
Affiliation  Indus International Hospital 
Address  Department of clinical trial. Indus International hospital Chandigarh Ambala Highway Derabassi SAS Nagar Rupnagar PUNJAB 140507 India
Department of clinical trial. Indus International hospital Chandigarh Ambala Highway Derabassi SAS Nagar Rupnagar PUNJAB 140507 India
Rupnagar
PUNJAB
140507
India 
Phone  7991451277  
Fax    
Email  avantikabiotech2017@gmail.com  
 
Source of Monetary or Material Support  
NIL 
 
Primary Sponsor  
Name  Indus International Hospital 
Address  Indus International Hospital Ambala Chandigarh Highway Derabassi SAS Nagar Rupnagar Punjab 140507 INDIA  
Type of Sponsor  Research institution and hospital 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Awantika Chandra  Indus International Hospital  Indus International Hospital Ambala Chandigarh Highway Derabassi SAS Nagar Rupnagar Punjab 140507 INDIA
Rupnagar
PUNJAB 		 79914515277

avantikabiotech2017@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
Indus International Hospital Institutional Ethics Committee  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: A00-B99||Certain infectious and parasitic diseases,  
 
Intervention / Comparator Agent  
Type  Name  Details 
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  99.00 Year(s)
Gender  Both 
Details  Age 18 or more than 18 years
Admitted with suspected or confirmed bacterial infection
Received at least one antibiotic prescription and AST testing
 
 
ExclusionCriteria 
Details  Viral or fungal infections without bacterial co-infection
Antibiotic prescribed as prophylactic
Discharged against medical advice
Outpatients, patients with incomplete medical records
 
 
Method of Generating Random Sequence   Not Applicable 
Method of Concealment   Not Applicable 
Blinding/Masking   Not Applicable 
Primary Outcome  
Outcome  TimePoints 
To determine the proportion of antibiotic prescriptions that comply with rational antibiotic use when guided by AST results and antimicrobial stewardship recommendations  At baseline 
 
Secondary Outcome  
Outcome  TimePoints 
To describe resistance & susceptibility patterns among bacterial pathogens isolated from clinical specimens.

To measure the duration of antibiotic therapy in relation to AST findings.

To evaluate the frequency of antibiotic de-escalation or escalation following receipt of AST results.

To assess adverse events associated with antibiotic therapy. 		 At baseline & 5th day 
 
Target Sample Size   Total Sample Size="100"
Sample Size from India="100" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   N/A 
Date of First Enrollment (India)   29/12/2025 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="0"
Months="6"
Days="0" 
Recruitment Status of Trial (Global)
Modification(s)  		 Not Applicable 
Recruitment Status of Trial (India)  Open to Recruitment 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary  

Antibiotics are a cornerstone of modern clinical practice, playing a critical role in the management of infectious diseases across outpatient, inpatient, and intensive-care settings. Unfortunately, due to their widespread misuse and overuse drive the global surge in antimicrobial resistance (AMR). AMR limits therapeutic options, increases morbidity and mortality, and leads to greater financial strain on healthcare systems.

Antibiotic susceptibility testing (AST) serves as a approach to optimize antibiotic decision-making by identifying pathogens and quantifying their susceptibility to various antibiotics, AST bridges the gap between empiric therapy and targeted therapy. Empiric regimens, though essential in acute settings, frequently rely on broad-spectrum agents. These medications are valuable for rapid coverage but may contribute disproportionately to AMR.

 
Close